Lantheus Holdings, Inc
LNTH
$100.98
-1.79%
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to help clinicians find, fight, and follow diseases, primarily cancer. The company operates as a key player in the specialized drug manufacturing sector, with a portfolio segmented into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. The current investor narrative is heavily centered on the growth trajectory of its key oncology product, PYLARIFY, and the company's strategic positioning within the expanding field of targeted radiopharmaceuticals, which is driving significant revenue growth and market attention.…
LNTH
Lantheus Holdings, Inc
$100.98
Investment Opinion: Should I buy LNTH Today?
Rating & Thesis: The synthesized recommendation is Hold. While LNTH possesses a strong balance sheet and cash-generating business, its current valuation and technical overextension, coupled with decelerating revenue growth, limit the near-term upside and increase downside risk, making it prudent to wait for a better entry point or clearer signs of growth re-acceleration. This aligns with the mixed analyst sentiment, which includes a recent downgrade to 'Hold'.
Supporting Evidence: The stock trades at a forward P/E of 16.07x, which is reasonable but not compelling given the 4% YoY revenue growth. Profitability is strong, with a Q4 operating margin of 18.97% and robust TTM free cash flow of $348.64M. The balance sheet is a clear positive, with a debt-to-equity of 0.0007 and a current ratio of 2.70. However, the stock's proximity to its 52-week high (99%) after a 62% 6-month run suggests limited immediate upside without a fundamental catalyst.
Risks & Conditions: The two biggest risks are 1) failure to re-accelerate revenue growth beyond 4%, and 2) a technical reversal from overbought levels triggering a sharp correction. This Hold rating would upgrade to a Buy if the stock pulls back significantly (e.g., towards the $70-80 range, offering a better risk/reward) or if quarterly revenue growth re-accelerates convincingly above 10% YoY. It would downgrade to a Sell if revenue growth turns negative or gross margins show sustained contraction below 55%. Relative to its own history (trailing PE compression from 31x) and its current growth profile, the stock appears fairly valued to slightly overvalued in the near term.
Sign up to view all
LNTH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The fundamental picture is bifurcated: superb financial health and profitability are offset by slowing top-line growth and high dependence on a single product. Technically, the stock is overbought, suggesting limited near-term upside without a fundamental catalyst. The base case of consolidation is most likely. The stance would upgrade to bullish on a pullback to the $80-$85 range (offering a better entry) coupled with evidence of revenue growth stabilization above 8%. It would downgrade to bearish on a breakdown below key technical support (e.g., $90) accompanied by a quarterly revenue miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lantheus Holdings, Inc's 12-month outlook, with a consensus price target around $131.27 and implied upside of +30.0% versus the current price.
Average Target
$131.27
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$81 - $131
Analyst target range
Analyst coverage is limited, with only 4 analysts providing estimates, indicating this is a mid-cap stock with less institutional scrutiny. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include actions like 'Buy', 'Outperform', and 'Market Outperform', though one notable downgrade from 'Buy' to 'Hold' occurred in late February 2026. The average revenue estimate for the period is $2.19 billion, with a range from $2.10 billion to $2.41 billion, reflecting a moderate spread of about 14.5% between the low and high targets, which signals a reasonable level of consensus on the near-term business outlook. The wide target price range inherent in such limited coverage can lead to higher volatility, as price discovery is less efficient compared to heavily covered large-cap stocks.
Bulls vs Bears: LNTH Investment Factors
The bull case, driven by explosive technical momentum, a pristine balance sheet, and strong cash generation, currently holds stronger evidence, as reflected in the stock's powerful price action and solid profitability metrics. However, the bear case presents a credible counter-argument centered on decelerating revenue growth and product concentration. The single most important tension in the investment debate is whether the company's current premium valuation and technical overextension can be justified by a re-acceleration of top-line growth beyond the recent 4% pace, or if the market has gotten ahead of the underlying fundamentals. The resolution of this growth trajectory will be the primary determinant of future stock performance.
Bullish
- Explosive Momentum and Technical Strength: The stock has surged 62.43% over the past 6 months and 41.70% over the past 3 months, massively outperforming the S&P 500 by 52 and 29 percentage points, respectively. It is trading at 99% of its 52-week high, indicating sustained and powerful buying pressure. The negative beta of -0.08 suggests the stock moves independently of the broader market, offering potential portfolio diversification benefits.
- Robust Profitability and Cash Generation: The company generates strong cash flows, with TTM free cash flow of $348.64 million, enabling self-funded growth. Profitability is solid, with a Q4 gross margin of 59.21% and an operating margin of 18.97%, demonstrating pricing power and cost control in its niche. The business is solidly profitable, with Q4 net income of $54.09 million, a significant improvement from a net loss in the year-ago quarter.
- Exceptional Balance Sheet Strength: The company has a near-zero debt-to-equity ratio of 0.0007, indicating minimal financial leverage and risk. A current ratio of 2.70 provides ample liquidity to navigate market cycles. This fortress balance sheet provides significant strategic flexibility for M&A, R&D investment, or weathering downturns without dilution.
- Compelling Valuation Relative to Growth: The stock trades at a forward P/E of 16.07x, which is below its trailing P/E of 19.23x, implying the market is pricing in future earnings growth. The valuation has compressed from a recent historical high of 31.04x (Q3 2025) despite significant price appreciation, suggesting earnings have grown even faster. The PEG ratio is negative at -0.82, but this is likely due to a negative denominator from a temporary earnings fluctuation in Q4 2024, masking underlying growth.
Bearish
- Revenue Growth Deceleration and Volatility: Recent quarterly revenue growth has slowed to 4.01% YoY, a significant deceleration from the high-growth rates implied by the stock's momentum. The company's earnings are volatile, as evidenced by the swing from a net loss of -$11.79 million in Q4 2024 to a profit of $54.09 million in Q4 2025, raising questions about the sustainability of profitability.
- Extreme Technical Overextension: Trading at $102.82, the stock is just $1.07 from its 52-week high of $103.89, suggesting it may be overbought in the short term. The 1-month surge of 19.81% far outpaces the market's 4.6% gain, increasing the risk of a momentum-driven pullback. A high short ratio of 7.22 indicates significant bearish sentiment from short sellers betting on a reversal.
- Product Concentration Risk: The company's Radiopharmaceutical Oncology segment, driven by PYLARIFY, contributed $240.20 million of the $406.79 million total revenue in Q4, representing approximately 59% of total sales. This high dependence on a single product line creates significant risk if clinical, regulatory, or competitive pressures emerge against PYLARIFY. Diversification into other segments (Precision Diagnostics, Strategic Partnerships) remains a work in progress.
- Limited Analyst Coverage and High Volatility Risk: With only 4 analysts covering the stock, price discovery is less efficient, potentially leading to higher volatility and exaggerated price moves. The limited coverage pool also means the stock is more susceptible to significant re-ratings based on a single analyst's report, as seen with a recent downgrade from 'Buy' to 'Hold' in February 2026.
LNTH Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +29.12% and a 6-month surge of +62.43%. As of the latest close at $102.82, the price is trading near the top of its 52-week range, approximately 99% of the way from its 52-week low of $47.25 to its high of $103.89, indicating strong momentum but also potential overextension. Recent momentum has been exceptionally strong, with the stock up 19.81% over the past month and 41.70% over the past three months, significantly outpacing the broader market's gains of 4.6% and 12.6%, respectively, over the same periods. This acceleration suggests the uptrend is gaining strength, though the proximity to the 52-week high presents a clear technical resistance level. Key support is anchored at the 52-week low of $47.25, while immediate resistance is at the 52-week high of $103.89; a decisive breakout above this level could signal a continuation of the bullish trend. Notably, the stock's beta of -0.08 indicates it has exhibited low correlation with market movements, trading with its own unique volatility profile, which is unusual for a growth-oriented healthcare stock.
Beta
-0.04
-0.04x market volatility
Max Drawdown
-53.6%
Largest decline past year
52-Week Range
$47-$104
Price range past year
Annual Return
+25.7%
Cumulative gain past year
| Period | LNTH Return | S&P 500 |
|---|---|---|
| 1m | +17.2% | -0.0% |
| 3m | +39.2% | +8.7% |
| 6m | +59.5% | +8.0% |
| 1y | +25.7% | +23.1% |
| ytd | +50.1% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LNTH Fundamental Analysis
Revenue growth is robust, with the most recent quarterly revenue at $406.79 million, representing a year-over-year growth of 4.01%. Segment data reveals the primary driver is the Radiopharmaceutical Oncology line, specifically PYLARIFY, which contributed $240.20 million, underscoring its dominance in the product portfolio. The company is solidly profitable, reporting net income of $54.09 million for the quarter and a trailing twelve-month free cash flow of $348.64 million, indicating strong cash generation. Profitability metrics are healthy, with a gross margin of 59.21% for the quarter and an operating margin of 18.97%, demonstrating effective cost management and pricing power within its niche. The balance sheet is exceptionally strong, featuring a minimal debt-to-equity ratio of 0.0007 and a robust current ratio of 2.70, which signifies ample liquidity and a very low financial risk profile, allowing the company to internally fund growth initiatives and strategic investments.
Quarterly Revenue
$406786000.0B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$348639000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LNTH Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 19.23x and a forward PE of 16.07x. The lower forward multiple suggests the market anticipates earnings growth, as it prices in higher future profits. Compared to sector averages, specific industry comparison data is not available in the provided dataset, preventing a direct peer premium/discount quantification. Historically, the current trailing PE of 19.23x sits below the stock's own recent historical highs seen in prior quarters, such as the 31.04x reported for Q3 2025, indicating the valuation has compressed relative to its recent past despite the significant price appreciation, potentially due to even faster earnings growth.
PE
19.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -498x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage, as the debt-to-equity ratio is a negligible 0.0007, but rather earnings volatility and product concentration. Net income swung from -$11.79M in Q4 2024 to +$54.09M in Q4 2025, raising questions about the predictability of earnings. Over 59% of Q4 revenue ($240.2M of $406.79M) came from the Radiopharmaceutical Oncology segment, heavily reliant on PYLARIFY. Any clinical setback, patent challenge, or competitive threat to this product could disproportionately impact revenue and investor sentiment, as the other segments are not yet large enough to offset a decline.
Market & Competitive Risks: The stock's primary market risk is valuation compression. Trading at a trailing P/E of 19.23x on just 4% YoY revenue growth, LNTH is priced for a growth re-acceleration. If growth remains subdued, the multiple could contract towards sector averages for slower-growth healthcare stocks. The negative beta of -0.08, while a diversifier, also indicates the stock trades on idiosyncratic news, making it vulnerable to company-specific disappointments. The high short interest (short ratio 7.22) suggests a cohort of investors is actively betting on a decline, which could amplify selling pressure on any negative catalyst.
Worst-Case Scenario: The worst-case scenario involves a combination of PYLARIFY facing unexpected competitive or regulatory pressure, causing revenue growth to stall or decline, coinciding with a broader market de-rating of growth stocks. This would trigger multiple compression and earnings downgrades. Given the stock's high momentum, a reversal could be severe. A realistic downside target is a return to the 52-week low of $47.25, representing a potential loss of approximately -54% from the current price of $102.82. The historical max drawdown of -53.92% provides a precedent for such a decline.
FAQ
The key risks are: 1) Product Concentration: Approximately 59% of Q4 revenue ($240.2M) came from the PYLARIFY-driven oncology segment; any setback here would be material. 2) Growth Deceleration: Recent quarterly revenue growth of 4.01% YoY is a sharp slowdown, calling the growth narrative into question. 3) Technical Overextension: After a 62% 6-month run, the stock is trading at 99% of its 52-week high, increasing vulnerability to a momentum reversal. 4) Earnings Volatility: Net income swung from a loss of -$11.79M to a profit of $54.09M year-over-year in Q4, highlighting earnings unpredictability. The concentrated, volatile business model coupled with a high-flying stock price presents the greatest risk.
The 12-month outlook presents three scenarios. The Base Case (55% probability) sees the stock trading between $95 and $110, assuming revenue growth stabilizes in the mid-single digits and profitability holds. The Bull Case (25% probability) targets $115-$130, requiring a re-acceleration of revenue growth to 15%+ and multiple expansion. The Bear Case (20% probability) warns of a drop to $47-$75 if growth stalls and the overextended price corrects sharply. The base case is most likely, driven by the assumption that strong cash flows and balance sheet support the valuation, but decelerating growth prevents significant multiple expansion in the near term.
LNTH appears fairly valued to slightly overvalued based on its current growth profile. It trades at a forward P/E of 16.07x and a trailing P/E of 19.23x. While these multiples are not extreme, they are being applied to a company with only 4% YoY revenue growth in its latest quarter. The valuation has compressed from a recent high of 31.04x (Q3 2025), indicating earnings have grown into the price. The market is pricing in an expectation of stable profitability and moderate growth. Without a re-acceleration of top-line growth, the current valuation leaves little room for multiple expansion, limiting upside.
LNTH is a Hold, not a clear Buy at current levels. The company has excellent fundamentals, including a near-zero debt load, strong cash flow ($348.64M TTM), and solid profitability (18.97% operating margin). However, the stock has surged 62% in 6 months and trades at 99% of its 52-week high, suggesting much of the near-term optimism is priced in. Furthermore, quarterly revenue growth has decelerated to 4% YoY. For a patient investor, it could become a good buy on a meaningful pullback (e.g., to the $80s) or if upcoming earnings show a re-acceleration of growth. The high short interest (ratio 7.22) adds volatility risk.
LNTH is more suitable for a medium-to-long-term investment horizon (2+ years) rather than short-term trading. While the stock exhibits high short-term volatility (beta of -0.08 indicates unique volatility), its long-term thesis depends on the sustained commercial success and pipeline development in radiopharmaceuticals, which takes years to unfold. The company pays no dividend, eliminating an income component. Short-term traders face high risk from the stock's overbought condition and high short interest. Long-term investors can better weather volatility while betting on the company's strong financial position and niche market opportunity, but they must be prepared for significant price swings along the way.